ABSTRACT

Objective: To develop and to perform process optimization of solid dosage form (Skeletal muscle relaxant) from lab scale to pilot scale. To done the following tests on newly formulated Cyclobenzaprine Hydrochloride tabletand done Disintegrationand Dissolution test. Method: Dry granulation is typically used in the manufacture of tablets if the formulation ingredients are too fluffy or too susceptible to flowability problems for direct compression to be a viable processing option and/or too susceptible to degradation from heat and/or moisture for wet granulation to be a viable processing option for densification. The process is sometimes chosen as an alternative to wet granulation when direct compression is not feasible not because wet granulation is not feasible but because the manufacturer is more experienced with dry granulation or to reduce processing time and/or equipment requirements to reduce costs. The direct compression method is used. Result: The formulation 5 (F5)- It passes the disintegration test and also it give best dissolution values because it gradually release the drug Cyclobenzaprine Hydrochloride on the formulation-5 (coated 2%) and in core tablet state itself also. Conclusion: The prepared Cyclobenzaprine Hydrochloride tablet formulation 5 (F5) passes the limits of disintegration and dissolution tests.
Publication date: 01/02/21

https://ijbpas.com/pdf/2021/February/MS_IJBPAS_2021_5369.pdf

Download PDF
https://doi.org/10.31032/IJBPAS/2021/10.2.5369